Clinical Trial

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

Study acronym: ENDURA-2
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.
Trial Details
NCT Number NCT06961214
Lead Sponsor GlaxoSmithKline
Conditions Pulmonary Disease, Chronic Obstructive
Enrollment 960 participants
Start Date 2025-06-23
Primary Completion 2029-08-21 (estimated)
Study Completion 2029-08-21 (estimated)
Updated on ClinicalTrials.gov 2026-04-09